Loading…
Improving Access to Addiction Medicine Providers Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,674 other S bills in the 119th — cohort avg 32d
Improving Access to Addiction Medicine Providers Act This bill provides statutory authority for the Minority Fellowship Program to include fellowships for training in the field of addiction medicine. (The Minority Fellowship Program, administered by the Substance Abuse and Mental Health Services Administration, funds fellowships for individuals seeking graduate degrees and planning to work on addressing mental or substance use disorders in racial and ethnic minority populations.)
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2025 · second_quarter · Pharmacy
Issues: 340B Program/Transparency; generics access; Pharmacy Benefit Managers; Prescription Drug Cost; Step Therapy Bills: S. 1114, Expanding Access to Low-Cost Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S. 2305 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] S. 775, Increasing Transparency in Generic Drug Applications To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] S.1542, DRUG Act To improve services provided by pharmacy benefit managers. Sponsor: Sen. Marshall, Roger [R-KS] S. 1067, Ensuring Timely Access to Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.5429 - Medication Affordability and Patent Integrity Act To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office. Sponsor: Rep. Kuster, Ann M. [D-NH-2] S.2780 - Medication Affordability and Patent Integrity Act To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office. Sponsor: Sen. Hassan, Margaret Wood [D-NH] S.1036 - Improving Access to Addiction Medicine Providers Act To amend the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Sponsor: Sen. Cornyn, John [R-TX]
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $120,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2025 · second_quarter · Pharmacy
340B Program; generics access; Pharmacy Benefit Managers; Prescription Drug Cost; Step Therapy S. 1114, Expanding Access to Low-Cost Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S. 2305 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] S.1542, DRUG Act To improve services provided by pharmacy benefit managers. Sponsor: Sen. Marshall, Roger [R-KS] S. 1067, Ensuring Timely Access to Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.5429 - Medication Affordability and Patent Integrity Act To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office. Sponsor: Rep. Kuster, Ann M. [D-NH-2] S.2780 - Medication Affordability and Patent Integrity Act To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office. Sponsor: Sen. Hassan, Margaret Wood [D-NH] S.1036 - Improving Access to Addiction Medicine Providers Act To amend the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Sponsor: Sen. Cornyn, John [R-TX]
Client expense: $10,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Pharmacy
340B Program/Transparency; generics access; Pharmacy Benefit Managers; Prescription Drug Cost; Step Therapy S. 1114, Expanding Access to Low-Cost Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S. 2305 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] S. 775, Increasing Transparency in Generic Drug Applications To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] S.1542, DRUG Act To improve services provided by pharmacy benefit managers. Sponsor: Sen. Marshall, Roger [R-KS] S. 1067, Ensuring Timely Access to Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.5429 - Medication Affordability and Patent Integrity Act To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office. Sponsor: Rep. Kuster, Ann M. [D-NH-2] S.2780 - Medication Affordability and Patent Integrity Act To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office. Sponsor: Sen. Hassan, Margaret Wood [D-NH] S.1036 - Improving Access to Addiction Medicine Providers Act To amend the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Sponsor: Sen. Cornyn, John [R-TX]
Client expense: $1,210,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2025 · first_quarter · Alcohol and Drug Abuse
Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing. Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule. Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction. Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes. Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. Lobbied to raise federal alcohol taxes
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2025 · first_quarter · Health Issues
Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing. Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule. Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction. Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes. Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. Lobbied to raise federal alcohol taxes
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2025 · first_quarter · Medical/Disease Research/Clinical Labs
Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing. Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule. Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction. Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes. Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. Lobbied to raise federal alcohol taxes
2025 · first_quarter · Medicare/Medicaid
Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing. Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule. Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction. Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes. Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. Lobbied to raise federal alcohol taxes
2025 · first_quarter · Budget/Appropriations
Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing. Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule. Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction. Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes. Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. Lobbied to raise federal alcohol taxes
2025 · first_quarter · Insurance
Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing. Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule. Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction. Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes. Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. Lobbied to raise federal alcohol taxes
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)